Search

Displaying results 4701 - 4710 of 10000 in total
  1. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. … It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.

  2. Drug

    Inecalcitol

    go.drugbank.com/drugs/DB04796
    Investigational

  3. Drug

    RTA 744

    go.drugbank.com/drugs/DB05920
    Investigational

    RTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers.

  4. Drug

    Col-118

    go.drugbank.com/drugs/DB05778
    Investigational

    It is a believed to reduce erythema by constricting enlarged blood vessels in facial tissue. … COL-118, a topical compound based on the SansRosa technology, for the treatment of redness associated with rosacea and other skin disorders.

  5. Drug

    Cypermethrin

    go.drugbank.com/drugs/DB13721
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Cyfluthrin

    go.drugbank.com/drugs/DB13828
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Stevioside

    go.drugbank.com/drugs/DB16882
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Fenspiride

    go.drugbank.com/drugs/DB08979
    Investigational

    Fenspiride is an oxazolidinone spiro compound used as a drug in the treatment of certain respiratory diseases. … It is approved for use in Russia for the treatment of acute and chronic inflammatory diseases of ENT organs and the respiratory tract (like rhinopharyngitis, laryngitis, tracheobronchitis, otitis and sinusitis

  9. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 is designed to act locally in the gastrointestinal tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain or its central nervous system … LX1031 is an orally-dosed drug candidate for irritable bowel syndrome and other gastrointestinal disorders.

  10. Drug

    Sodium sulfide

    go.drugbank.com/drugs/DB11159
    Approved

    Sodium sulfide is a chemical compound with a chemical formula Na2S. … H2S is an endogenous gaseous transmitter that exhibits anti-inflammatory and antiapoptotic properties.